Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIDENCE study of Copaxone three-times-weekly versus daily in relapsing-remitting multiple sclerosis
2015-000922-12Phase 4Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Medication satisfaction over 6 months. Started Oct 2015; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2015-000922-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000922-12.